ClinicalTrials.gg
CompletedNCT03796026Updated Apr 27, 2025

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

A Phase 1 interventional study of Seltorexant 40 mg and Placebo in Sleep Apnea, Obstructive, sponsored by Janssen Research & Development, LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
374th of 594
34 · median 49
Started
2019
with 41 others
Phase 1
26 of 753
4 open now
Registered
439th of 753
by date

Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 374th largest by enrollment of the 594 interventional ones that give a count, is one of 42 that started in 2019, is one of 26 in phase 1, and was the 439th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of multiple doses of seltorexant compared with placebo on respiration during sleep in adult participants with mild to moderate obstructive sleep apnea.

03

Conditions studied

  • Sleep Apnea, Obstructive
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be a women of non- (WONCBP) or man. A WONCBP is defined as: a) (postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy; b) Permanently sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy
  • Meet the International Classification of Sleep Disorder diagnostic criteria for obstructive sleep apnea (OSA) based on the investigator's assessment with or without sleep study. The OSA diagnosis can be confirmed by previous sleep studies, appropriate documentations (for example, medical records or letters from treating physicians) or documented conversation with the treating physician
  • Mild to moderate OSA, defined as AHI greater than or equal to (>=)5 to less than (\<)30, based on screening polysomnography (PSG)
  • (BMI) between 18 and 40 kilogram per meter square (kg/m\^2) (inclusive) (BMI = weight/height\^2)
  • Must be otherwise healthy based on physical examination, medical history, vital signs, 12-lead (ECG), and clinical laboratory tests performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. If the results of the clinical laboratory tests are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities from normal to be not or to be appropriate and reasonable for the population under study

Exclusion criteria

Exclusion Criteria:

  • Has a history of, or current signs and symptoms of, severe renal insufficiency ( \<30 milliliter per minute [mL/min]); moderate to severe hepatic insufficiency ( Score >=7), significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic, or endocrine disorders (including uncontrolled hypo- or hyperthyroidism or diabetes mellitus). Participants with diabetes mellitus who are under good control ( [HbA1c] \<= 8.5 percent [%] and fasting glucose \<=140 milligram per deciliter [mg/dL] at screening) may be eligible to participate if otherwise medically healthy, and if on a stable regimen of glucose-lowering medications for at least 2 months prior to screening
  • Screening PSG with oxygen (O2) saturation \<=80% for >=5% of total sleep time (TST)
  • Screening PSG with >=10 periodic limb movements per hour associated with an arousal
  • Currently using or used within 7 days of screening a continuous positive airway pressure (CPAP), a dental appliance, or home oxygen use for OSA, or required to use any of them for the duration of the study
  • Has other respiratory disorders such as (COPD) or asthma that need systemic and/or inhaled , bronchiectasis, or emphysema, documented by history or physical examination
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Seltorexant Followed by Placebo

    Participants will receive seltorexant (40 milligram \[mg\] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.

    Drug: Seltorexant 40 mg · Drug: Placebo

  • Experimental
    Placebo Followed by Seltorexant

    Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.

    Drug: Seltorexant 40 mg · Drug: Placebo

Interventions

  • Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

    Also known as: JNJ-42847922

  • DrugPlacebo

    Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

06

What researchers measure

Primary outcomes

  1. Apnea-Hypopnea Index (AHI) Score as Measured by Polysomnography (PSG)

    AHI score is used to indicate the severity of sleep apnea. The AHI is calculated by dividing the number of apnea events by the number of hours of sleep. The AHI values for adults are categorized as: Normal: AHI less than (\<)5, Mild sleep apnea: 5 less than or equal to (\<=) AHI \<15, Moderate sleep apnea: 15\<= AHI \<30, and Severe sleep apnea: AHI greater than or equal to (\>=)30.

    Time frame: Day 4

Secondary outcomes

  1. AHI Score as Measured by PSG

    AHI score is used to indicate the severity of sleep apnea. The AHI is calculated by dividing the number of apnea events by the number of hours of sleep. The AHI values for adults are categorized as: Normal: AHI \<5, Mild sleep apnea: 5\<= AHI \<15, Moderate sleep apnea: 15\<= AHI \<30, and Severe sleep apnea: AHI \>=30.

    Time frame: Day 1 (Night)

  2. Mean Oxygen Saturation (SpO2) During Total Sleep Time (TST)

    The mean SpO2 during TST on Night 4 and Night 1 will be assessed by continuous finger pulse oximetry.

    Time frame: Nights 1 and 4

  3. Mean SpO2 During Rapid Eye Movement (REM), Non-Rapid Eye Movement (NREM), and Awake Stages

    The mean SpO2 during REM, NREM and awake stages of sleep will be assessed by continuous finger pulse oximetry.

    Time frame: Nights 1 and 4

  4. Percentage of Total Sleep Time with SpO2 less than 90 percent (%), 85%, and 80%

    The percentage of TST with SpO2 level less than 90%, 85%, and 80% during the night, assessed by continuous finger pulse oximetry will be reported.

    Time frame: Nights 1 and 4

  5. Mean Latency to Persistent Sleep (LPS) as Assessed by PSG

    LPS is a sleep parameter and will be measured by PSG during PSG screening. Elapsed time from the beginning of the PSG recording to the onset of the first 10 minutes of continuous sleep will be measured over 4 nights and the average time to sleep will be calculated.

    Time frame: Nights 1 and 4

  6. Wake After Sleep Onset (WASO) by PSG

    WASO is a sleep parameter and will be measured by PSG during PSG screening. WASO is measured during overnight sleep laboratory PSG assessment and is defined as the duration of wakefulness from the onset of persistent sleep (that is, 10 consecutive minutes of sleep) over the first 6 hours of PSG assessment. The number of minutes in the Awake stage after the onset of persistent sleep to the end of the recording.

    Time frame: Nights 1 and 4

  7. Sleep Efficiency (SE) by PSG

    SE is a sleep parameter and will be measured by PSG during PSG screening. The total sleep time divided by the total time in bed (that is, the number of minutes from the beginning of the PSG recording to the end of the recording).

    Time frame: Days 1, 2, 3, and 4

  8. Total Sleep Time (TST)

    TST is a sleep parameter and will be measured by PSG during PSG screening. All of the hours of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep, as measured by PSG, are summed to determine the TST.

    Time frame: Nights 1 and 4

  9. Rapid Eye Movement (REM) Sleep Latency

    REM sleep is a normal stage of sleep characterized by the rapid and random movement of the eyes. REM sleep latency is the time from sleep onset until first period of REM sleep. PSG recordings will be used to determine the time spent in different sleep stages (S1: light sleep, S2: light sleep, S3: deep sleep, and S4: REM sleep).

    Time frame: Nights 1 and 4

  10. Total Duration of Rapid Eye Movement (REM) Sleep

    PSG recordings will be used to determine the time spent in different sleep stages (S1: light sleep, S2: light sleep, S3: deep sleep, and S4: REM sleep). It will be calculated as number of epochs scored as REM sleep divided by 2.

    Time frame: Nights 1 and 4

  11. NREM Sleep Latency

    NREM sleep latency is the time from sleep onset until first period of NREM sleep. Polysomnographic recordings will be used to determine the time spent in different sleep stages (S1: light sleep, S2: light sleep, S3: deep sleep, and S4: NREM sleep).

    Time frame: Nights 1 and 4

  12. Total Duration of NREM Sleep

    Polysomnographic recordings will be used to determine the time spent in different sleep stages (S1: light sleep, S2: light sleep, S3: deep sleep, and S4: NREM sleep). It will be calculated as number of epochs scored as NREM sleep divided by 2.

    Time frame: Nights 1 and 4

  13. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to end of study (approximately up to 9 weeks)

  14. Percentage of Participants with all Serious Adverse Events (SAEs) and Events of Special Interest

    An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. All SAEs and events of special interest including cataplexy (sudden, transient episode of muscle weakness accompanied by conscious awareness), sleep paralysis (the experience of not being able to move, react, or speak when falling asleep/awakening), and complex, sleep-related behaviors/parasomnias such as confusional arousals, somnambulism (sleep walking), sleep terrors, bruxism (teeth grinding), sleep sex, sleep related eating disorder, sleep behavior disorder, and catathrenia (Rapid Eye Movement \[REM\]-associated end-inspiratory apnea/breath holding) will be reported.

    Time frame: Baseline up to end of study (approximately up to 9 weeks)

  15. Number of Participants with Clinically Significant Vital Signs Abnormalities

    Number of participants with clinically significant abnormalities in the vital signs including temperature, pulse/heart rate, respiratory rate, and blood pressure will be reported.

    Time frame: Baseline up to end of study (approximately up to 9 weeks)

  16. Number of Participants with Clinically Significant Physical Examination Abnormalities

    Number of participants with clinically significant abnormalities in the physical examination including examination of height, body weight, and waist circumference will be reported.

    Time frame: Baseline up to end of study (approximately up to 9 weeks)

  17. Number of Participants with Clinically Significant Electrocardiogram (ECG) Abnormalities

    Number of participants with clinically significant abnormalities in the ECG will be reported.

    Time frame: Baseline up to end of study (approximately up to 9 weeks)

  18. Number of Participants with Clinically Significant Laboratory Abnormalities

    Blood samples for serum chemistry, hematology, and urinalysis will be collected for clinical laboratory testing.

    Time frame: Baseline up to end of study (approximately up to 9 weeks)

  19. Number of participants with suicidal ideation measured using Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a clinician rated assessment of suicidal behavior and / or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation indicates an increase in severity of suicidal ideation from baseline.

    Time frame: Baseline, Days 1, 2, 4, 5, and end of study (approximately 9 weeks)

  20. Bond-Lader Visual Analog Scales (B-L VAS) Score

    The B-L VAS is a patient-rated scale designed to assess the current level of sedation and consists of sixteen 100-milliliter (mm) VAS anchored by antonyms (Alert-Drowsy, Lethargic-Energetic). Scores are combined to form 3 mood factors: alertness, calmness, and contentedness. The score is measured from the left to a mark made on the line by the patient and ranges from 0 (alert) to 100 (drowsy).

    Time frame: Baseline, Day 2, and Day 5

  21. Next-Day Residual Effect Measured by the Karolinska Sleepiness Scale (KSS) Score

    The KSS is a patient reported assessment of level of drowsiness at the time of scale administration. This scale is focused mainly on the propensity to fall asleep and has a high validity in measuring sleepiness. It consists of a 9-point Likert scale with response options from: 1=very alert, 3=alert, 5=neither alert nor sleepy, 7=sleepy (but not fighting sleep), 9=very sleepy (fighting sleep).

    Time frame: Baseline, Day 2, and Day 5

  22. Residual Effect on a Cognitive Test Battery Evaluated by Symbol Digit Modalities Test (SDMT)

    The SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and has been used to demonstrate worse cognitive functioning in patients with MDD. The test includes a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant is presented with randomly ordered symbols and is required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds is recorded by examiner-administered cognitive test battery.

    Time frame: Baseline and Day 5

  23. Performance Score on a Cognitive Test Battery Evaluated by Trail Making Test Form B (TMT-B)

    The TMT-B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1-A-2-B). The participant is instructed to work as quickly as possible while still maintaining accuracy. The TMT-B has acceptable reliability; reliability coefficients have typically been reported as exceeding 0.65. The TMT-B is sensitive to cognitive decline associated with MDD.

    Time frame: Baseline and Day 5

  24. Residual Effect on Cognitive Function Measured by Hopkins Verbal Learning Test-Revised (HVLT-R)

    The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

    Time frame: Baseline and Day 5

07

Study locations

4 sites
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Clinilabs
    New York, New York 10019, United States
  • CTI Clinical Trial and Consulting Services
    Cincinnati, Ohio 45212, United States
  • AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company
    Knoxville, Tennessee 37923, United States
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jun 2019, 5 months.

Of 27 phase 1 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2019
First posted
Jan 8, 2019
StartActual
Jan 4, 2019
Primary completionActual
Jun 7, 2019
CompletionActual
Jun 14, 2019
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03796026
Responsible party
Sponsor
First posted
Jan 8, 2019
Start date
Jan 4, 2019
Primary completion
Jun 7, 2019
Completion
Jun 14, 2019
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion